Table of Contents
ISRN Analytical Chemistry
Volume 2012, Article ID 135208, 4 pages
Research Article

Development and Validation of HPTLC Method for Estimation of Safinamide Mesylate in Bulk and in Tablet Dosage Form

Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education & Research, Dhule District, Shirpur 425 405, India

Received 1 January 2012; Accepted 14 February 2012

Academic Editors: G. Drochioiu, G. Erny, A. Jimenez, and G. Vecchio

Copyright © 2012 Vivekkumar K. Redasani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Onofrj, L. Bonanni, and A. Thomas, “An expert opinion on safinamide in Parkinson's disease,” Expert Opinion on Investigational Drugs, vol. 17, no. 7, pp. 1115–1125, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Marzo, L. Dal Bo, N. C. Monti et al., “Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity,” Pharmacological Research, vol. 50, no. 1, pp. 77–85, 2004. View at Publisher · View at Google Scholar
  3. K. Zhang, N. Xue, X. Shi, W. Liu, J. Meng, and Y. Du, “A validated chiral liquid chromatographic method for the enantiomeric separation of safinamide mesilate, a new anti-Parkinson drug,” Journal of Pharmaceutical and Biomedical Analysis, vol. 55, no. 1, pp. 220–224, 2011. View at Publisher · View at Google Scholar
  4. L. Dal Bo, P. Mazzucchelli, M. Fibbioli, and A. Marzo, “Bioassay of safinamide in biological fluids of humans and various animal species,” Drug Research, vol. 56, no. 12, pp. 814–819, 2006. View at Google Scholar · View at Scopus
  5. ICH-Guidelines Q2A, “Validation of Analytical Procedures: Definition and terminology,” (CPMP III/5626/94), Geneva, Switzerland, 1995.
  6. ICH-Guidelines Q2B, “Validation of Analytical Procedures: Methodology,” (CPMP/ICH/281/95) Geneva, Switzerland 1996.